Tag: biotechnology
-
Inhaled Dry-Powder Covid-19 Antibodies in the Works
Two biotechnology companies are developing synthetic antibodies to treat Covid-19 infections formulated as an inhaled dry powder rather than an infusion.
-
Covid-19 Drug Biotech Raises $300M in IPO
A company developing a treatment for Covid-19 infections taken as a tablet instead of infusion issued its initial public offering, or IPO, for common stock.
-
Covid-19 Antibodies Cut Viral Load, Medical Visits
Interim results from a clinical trial show a synthetic antibody drug reduces viral burden and medical visits among non-hospitalized Covid-19 patients.
-
200M Covid-19 Vaccine Doses Donated to Int’l Effort
Sanofi and GlaxoSmithKline are offering 200 million doses of their Covid-19 vaccine for a project devoted to making vaccines equitably available worldwide.
-
Novartis Gains Synthetic Protein Therapies for Covid-19
Global drug maker Novartis is gaining access to two Covid-19 therapy candidates made from a library of synthetic protein components.
-
Lilly, NIH Halt Covid-19 Antibody Therapy Trial
Drug maker Eli Lilly and National Institutes of Health are stopping a clinical trial testing a synthetic antibody to treat hospitalized Covid-19 patients.
-
Bayer Gains Gene Therapy Biotech in $4B Deal
Global drug maker Bayer AG is acquiring the company Asklepios BioPharmaceutical, developer of gene therapies to treat inherited disorders.
-
Precision Drug Trial Shows Solid Tumor Shrinkage
Partial results from a clinical trial show a drug to stop specific cancer-causing proteins shrinks advanced tumors in some patients across several tumor types.
-
Start-Up Developing Engineered B-Cell Therapies
A new enterprise, spun off from Seattle Children’s Research Institute, is creating therapeutics for diseases from engineered B-cells in the immune system.
-
Roche Gains Covid-19 Oral Drug Candidate
Global drug maker Roche Group is acquiring an experimental antiviral therapy for Covid-19 infections taken as a oral drug, rather than an infusion.